Molina Healthcare (MOH) Stock Forecast & Price Target

$314.18 -5.44 (-1.70%)

As of 12:53 PM Eastern

Molina Healthcare - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 15 Analyst Ratings

Sell
0

Hold
9

Buy
6

Based on 15 Wall Street analysts who have issued ratings for Molina Healthcare in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 9 have given a hold rating, and 6 have given a buy rating for MOH.

Consensus Price Target

$365.38
16.30% Upside

According to the 15 analysts' twelve-month price targets for Molina Healthcare, the average price target is $365.38. The highest price target for MOH is $414.00, while the lowest price target for MOH is $297.00. The average price target represents a forecasted upside of 16.30% from the current price of $314.19.

Get the Latest News and Ratings for MOH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Molina Healthcare and its competitors.

MOH Analyst Ratings Over Time

Type	Current Forecast 5/22/24 to 5/22/25	1 Month Ago 4/22/24 to 4/22/25	3 Months Ago 2/22/24 to 2/21/25	1 Year Ago 5/23/23 to 5/22/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$365.38	$363.62	$353.17	$404.90
Forecasted Upside	16.30% Upside	13.21% Upside	24.40% Upside	17.23% Upside
Consensus Rating	Hold	Hold	Hold	Hold

MOH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MOH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Molina Healthcare Stock vs. The Competition

Type	Molina Healthcare	Medical Companies	S&P 500
Consensus Rating Score	2.40	2.81	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	14.16% Upside	4,200.67% Upside	15.78% Upside
News Sentiment Rating	Positive News See Recent MOH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/25/2025	Barclays 3 of 5 stars	Andrew Mok Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$339.00 ➝ $362.00	+15.15%
4/22/2025	Sanford C. Bernstein 3 of 5 stars	Lance Wilkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$414.00	+37.24%
4/15/2025	Baird R W 0 of 5 stars	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$331.00 ➝ $375.00	+7.47%
4/11/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Macdonald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$340.00 ➝ $400.00	+16.57%
4/9/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Cassorla Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
4/9/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$376.00 ➝ $400.00	+21.19%
3/5/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$295.00 ➝ $372.00	+21.56%
2/7/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$374.00 ➝ $325.00	+13.15%
2/6/2025	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Raj Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$345.00 ➝ $345.00	+19.20%
Get the Latest News and Ratings for MOH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Molina Healthcare and its competitors with MarketBeat's FREE daily newsletter.
12/17/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral	$378.00 ➝ $350.00	+18.42%
10/24/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$406.00 ➝ $406.00	+22.41%
7/29/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$354.00 ➝ $353.00	+6.02%
7/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$354.00 ➝ $297.00	+2.86%
7/24/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$412.00 ➝ $351.00	+21.57%
3/28/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$439.00	+4.90%
7/14/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$365.00	+21.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:54 PM ET.

Should I Buy Molina Healthcare Stock? MOH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 19, 2025. Please send any questions or comments about these Molina Healthcare pros and cons to contact@marketbeat.com.

Molina Healthcare
Bull Case

Here are some ways that investors could benefit from investing in Molina Healthcare, Inc.:

The current stock price is around $325, which is near its one-year high, indicating strong market performance.
Recent upgrades from analysts, including a shift from a "hold" to a "buy" rating, suggest positive sentiment and potential for growth.
The company has a solid market capitalization of approximately $17.62 billion, reflecting its stability and presence in the healthcare sector.
Molina Healthcare, Inc. operates in multiple segments, including Medicaid and Medicare, which diversifies its revenue streams and reduces risk.
Analysts have set an average target price of $365.38, indicating potential upside for investors based on current valuations.

Molina Healthcare
Bear Case

Investors should be bearish about investing in Molina Healthcare, Inc. for these reasons:

Insider selling activity, including significant sales by the CEO, may raise concerns about the company's future prospects and insider confidence.
The stock has experienced fluctuations, with a one-year low of $262.32, indicating potential volatility that could affect investment returns.
Despite recent upgrades, the consensus rating remains a "hold," suggesting that analysts are cautious about immediate growth potential.
The company's debt-to-equity ratio of 0.69 indicates a moderate level of debt, which could pose risks in a rising interest rate environment.
Recent downgrades from some analysts may signal mixed opinions about the stock's future performance, leading to uncertainty for investors.

MOH Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Molina Healthcare is $365.38, with a high forecast of $414.00 and a low forecast of $297.00.
: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molina Healthcare in the last year. There are currently 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MOH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOH, but not buy additional shares or sell existing shares.
: According to analysts, Molina Healthcare's stock has a predicted upside of 16.30% based on their 12-month stock forecasts.
: Over the previous 90 days, Molina Healthcare's stock had 1 upgrade and 1 downgrade by analysts.
: Molina Healthcare has been rated by research analysts at Baird R W, Barclays, Guggenheim, Mizuho, Robert W. Baird, Sanford C. Bernstein, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Molina Healthcare less than other "medical" companies. The consensus rating for Molina Healthcare is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MOH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:MOH) was last updated on 5/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Molina Healthcare (MOH) Stock Forecast & Price Target